Immune-Checkpoint Blockade and Active Immunotherapy for Glioma

Cancer immunotherapy has made tremendous progress, including promising results in patients with malignant gliomas. Nonetheless, the immunological microenvironment of the brain and tumors arising therein is still believed to be suboptimal for sufficient antitumor immune responses for a variety of rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Brian J., Pollack, Ian F., Okada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875944/
https://www.ncbi.nlm.nih.gov/pubmed/24202450
http://dx.doi.org/10.3390/cancers5041379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875944/
https://www.ncbi.nlm.nih.gov/pubmed/24202450
http://dx.doi.org/10.3390/cancers5041379

Ejemplares similares